Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pelvic Organ Prolapse | 4 | 2023 | 134 | 1.840 |
Why?
|
| Suburethral Slings | 4 | 2023 | 76 | 1.840 |
Why?
|
| Urinary Incontinence, Stress | 3 | 2023 | 183 | 1.380 |
Why?
|
| Pelvic Floor | 4 | 2022 | 138 | 0.970 |
Why?
|
| Fecal Incontinence | 3 | 2021 | 240 | 0.820 |
Why?
|
| Urinary Incontinence | 4 | 2021 | 494 | 0.720 |
Why?
|
| Anal Canal | 1 | 2021 | 376 | 0.640 |
Why?
|
| Sarcoma, Endometrial Stromal | 1 | 2017 | 91 | 0.550 |
Why?
|
| Urology | 1 | 2021 | 397 | 0.540 |
Why?
|
| Gynecology | 1 | 2021 | 509 | 0.510 |
Why?
|
| Physicians, Women | 1 | 2021 | 487 | 0.490 |
Why?
|
| Exercise Therapy | 1 | 2021 | 904 | 0.480 |
Why?
|
| Delivery, Obstetric | 1 | 2021 | 904 | 0.470 |
Why?
|
| Burnout, Professional | 1 | 2021 | 690 | 0.410 |
Why?
|
| Menopause | 1 | 2018 | 1621 | 0.350 |
Why?
|
| Uterine Neoplasms | 1 | 2017 | 1513 | 0.300 |
Why?
|
| Postoperative Complications | 5 | 2023 | 15244 | 0.280 |
Why?
|
| Telemedicine | 1 | 2022 | 2853 | 0.250 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 5724 | 0.210 |
Why?
|
| Rectal Prolapse | 1 | 2022 | 30 | 0.210 |
Why?
|
| Ligaments | 1 | 2022 | 127 | 0.200 |
Why?
|
| Myofascial Pain Syndromes | 1 | 2019 | 35 | 0.170 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 6347 | 0.170 |
Why?
|
| Surgical Mesh | 1 | 2021 | 256 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 9185 | 0.160 |
Why?
|
| Uterus | 1 | 2022 | 710 | 0.160 |
Why?
|
| Female | 23 | 2023 | 379592 | 0.160 |
Why?
|
| Ureter | 1 | 2020 | 374 | 0.150 |
Why?
|
| Pelvic Pain | 1 | 2019 | 273 | 0.150 |
Why?
|
| Urinary Catheterization | 1 | 2018 | 201 | 0.150 |
Why?
|
| Vagina | 1 | 2022 | 825 | 0.150 |
Why?
|
| Urination Disorders | 1 | 2018 | 241 | 0.140 |
Why?
|
| Aorta, Abdominal | 1 | 2020 | 645 | 0.140 |
Why?
|
| Injections | 1 | 2019 | 840 | 0.140 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2019 | 212 | 0.140 |
Why?
|
| Pessaries | 1 | 2015 | 17 | 0.130 |
Why?
|
| Pelvis | 1 | 2020 | 730 | 0.130 |
Why?
|
| Retrospective Studies | 8 | 2023 | 77098 | 0.130 |
Why?
|
| Surgical Instruments | 1 | 2018 | 394 | 0.130 |
Why?
|
| Urination | 1 | 2016 | 204 | 0.120 |
Why?
|
| Postpartum Period | 1 | 2021 | 1078 | 0.120 |
Why?
|
| Consumer Health Information | 1 | 2016 | 210 | 0.120 |
Why?
|
| Quality of Life | 4 | 2021 | 12730 | 0.110 |
Why?
|
| HLA-DR Antigens | 1 | 1994 | 644 | 0.110 |
Why?
|
| Skin Tests | 1 | 1994 | 612 | 0.110 |
Why?
|
| Humans | 21 | 2023 | 742088 | 0.100 |
Why?
|
| Epidermal Cyst | 1 | 2012 | 62 | 0.100 |
Why?
|
| Prevalence | 2 | 2021 | 15194 | 0.100 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 24913 | 0.100 |
Why?
|
| Markov Chains | 1 | 2015 | 969 | 0.100 |
Why?
|
| Vaginal Diseases | 1 | 2012 | 102 | 0.100 |
Why?
|
| Middle Aged | 10 | 2022 | 213127 | 0.100 |
Why?
|
| Leiomyoma | 1 | 2017 | 728 | 0.100 |
Why?
|
| Health Surveys | 1 | 2021 | 4030 | 0.090 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 1066 | 0.090 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2015 | 1679 | 0.080 |
Why?
|
| Wounds and Injuries | 1 | 2021 | 2400 | 0.080 |
Why?
|
| Women's Health | 1 | 2017 | 2034 | 0.070 |
Why?
|
| Constipation | 2 | 2021 | 546 | 0.070 |
Why?
|
| Hypersensitivity | 1 | 1994 | 1093 | 0.070 |
Why?
|
| Registries | 1 | 2021 | 8077 | 0.060 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 1952 | 0.060 |
Why?
|
| Adult | 7 | 2021 | 213712 | 0.060 |
Why?
|
| Incidence | 1 | 2023 | 20928 | 0.060 |
Why?
|
| Kidney | 1 | 2020 | 7167 | 0.060 |
Why?
|
| Aged | 4 | 2022 | 162944 | 0.060 |
Why?
|
| Massachusetts | 1 | 2017 | 8662 | 0.060 |
Why?
|
| Antigens, CD | 1 | 1994 | 4024 | 0.060 |
Why?
|
| Internet | 1 | 2016 | 3062 | 0.060 |
Why?
|
| Recurrence | 1 | 2015 | 8333 | 0.060 |
Why?
|
| Clinical Competence | 1 | 2018 | 4681 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 5385 | 0.050 |
Why?
|
| Pandemics | 1 | 2022 | 8328 | 0.050 |
Why?
|
| Skin | 1 | 1994 | 4353 | 0.050 |
Why?
|
| United States | 4 | 2021 | 69693 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2022 | 62966 | 0.040 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2022 | 336 | 0.040 |
Why?
|
| Urinary Retention | 1 | 2019 | 110 | 0.040 |
Why?
|
| Neuromuscular Agents | 1 | 2019 | 134 | 0.040 |
Why?
|
| Risk Factors | 2 | 2021 | 72145 | 0.030 |
Why?
|
| Critical Pathways | 1 | 2020 | 475 | 0.030 |
Why?
|
| Dermatitis, Irritant | 1 | 1994 | 17 | 0.030 |
Why?
|
| Search Engine | 1 | 2016 | 144 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2016 | 512 | 0.030 |
Why?
|
| Urodynamics | 1 | 2016 | 347 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2017 | 40450 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2016 | 546 | 0.030 |
Why?
|
| Bartholin's Glands | 1 | 2012 | 5 | 0.030 |
Why?
|
| Urinary Tract Infections | 1 | 2019 | 786 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2018 | 1839 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2016 | 1003 | 0.030 |
Why?
|
| Vulvar Diseases | 1 | 2012 | 61 | 0.030 |
Why?
|
| Salicylanilides | 1 | 1991 | 15 | 0.030 |
Why?
|
| Antigens, CD1 | 1 | 1994 | 437 | 0.030 |
Why?
|
| Haptens | 1 | 1991 | 166 | 0.020 |
Why?
|
| Photosensitivity Disorders | 1 | 1991 | 78 | 0.020 |
Why?
|
| Alpha-Globulins | 1 | 1990 | 29 | 0.020 |
Why?
|
| Hyalin | 1 | 1990 | 37 | 0.020 |
Why?
|
| Langerhans Cells | 1 | 1991 | 173 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2020 | 2245 | 0.020 |
Why?
|
| Naphthalenes | 1 | 1990 | 194 | 0.020 |
Why?
|
| Epidermis | 1 | 1991 | 527 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2018 | 6452 | 0.020 |
Why?
|
| Allergens | 1 | 1994 | 1314 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2018 | 9846 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2019 | 12017 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 1990 | 2145 | 0.010 |
Why?
|
| Young Adult | 2 | 2016 | 56350 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 12958 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 20086 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2021 | 53187 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 35342 | 0.010 |
Why?
|
| Rats, Inbred BUF | 1 | 1990 | 19 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 57683 | 0.010 |
Why?
|
| Dermatitis, Contact | 1 | 1991 | 129 | 0.010 |
Why?
|
| Electrophoresis | 1 | 1990 | 240 | 0.010 |
Why?
|
| Kidney Cortex | 1 | 1990 | 186 | 0.010 |
Why?
|
| Male | 3 | 2018 | 349538 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1991 | 876 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 1990 | 862 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1990 | 2191 | 0.010 |
Why?
|
| Adolescent | 1 | 2016 | 85649 | 0.000 |
Why?
|
| Antigen-Presenting Cells | 1 | 1991 | 969 | 0.000 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1991 | 1470 | 0.000 |
Why?
|
| Ultraviolet Rays | 1 | 1991 | 1059 | 0.000 |
Why?
|
| Species Specificity | 1 | 1990 | 2479 | 0.000 |
Why?
|
| Microscopy, Fluorescence | 1 | 1991 | 2699 | 0.000 |
Why?
|
| Lymphocytes | 1 | 1991 | 2614 | 0.000 |
Why?
|
| Mice, Inbred BALB C | 1 | 1991 | 6382 | 0.000 |
Why?
|
| Flow Cytometry | 1 | 1991 | 5975 | 0.000 |
Why?
|
| Lymphocyte Activation | 1 | 1991 | 5519 | 0.000 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1991 | 10943 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1991 | 19223 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 1 | 1991 | 9274 | 0.000 |
Why?
|
| Rats | 1 | 1990 | 24265 | 0.000 |
Why?
|
| Animals | 2 | 1991 | 168561 | 0.000 |
Why?
|
| Mice | 1 | 1991 | 81045 | 0.000 |
Why?
|
Concepts
(137)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(13)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_